CA Patent

CA3013783A1 — Rapaglutins, novel inhibitors of glut and use thereof

Assigned to Johns Hopkins University · Expires 2017-08-10 · 9y expired

What this patent protects

Compounds with the following structures and their analogs are provided. Compositions that include these structures can be used to inhibit glucose transporters and stop or decrease the proliferation of cancer, treat possible organ rejection and treat autoimmune disease.

USPTO Abstract

Compounds with the following structures and their analogs are provided. Compositions that include these structures can be used to inhibit glucose transporters and stop or decrease the proliferation of cancer, treat possible organ rejection and treat autoimmune disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA3013783A1
Jurisdiction
CA
Classification
—
Expires
2017-08-10
Drug substance claim
No
Drug product claim
No
Assignee
Johns Hopkins University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.